Article Text

This article has a correction. Please see:

other Versions

The effects of the 5-HT2C agonist m-chlorophenylpiperazine on elite athletes suffering from unexplained underperformance syndrome (overtraining)
  1. Richard Budgett
  1. British Olympic Association, United Kingdom
    1. Natalie Hiscock
    1. University of Oxford, United Kingdom
      1. Ricardo M Arida
      1. University of Oxford, United Kingdom
        1. Linda M Castell (lindy.castell{at}
        1. University of Oxford, United Kingdom


          The central fatigue hypothesis describes a possible link between the neurotransmitter, 5-hydroxytryptamine (5-HT), plasma tryptophan and branched chain amino acids concentration and exercise-induced fatigue. Recent investigations studied 5-HT receptors and neuroendocrine "challenge” tests, using prolactin release as an indirect measure of 5-HT activity. The present study combined the original hypothesis about the role of amino acids in increasing brain 5-HT with a neuroendocrine challenge test on elite athletes diagnosed with unexplained, underperformance syndrome (UUPS). There was an apparent increased sensitivity of 5-HT receptors in athletes with UUPS compared with fit, well-trained controls, as measured via increased prolactin release following a bolus dose of m-chlorophenylpiperazine, a 5-HT agonist. No changes were observed in plasma amino acid concentrations in either group. There is evidence that well-trained athletes have a reduced sensitivity of 5-HT receptors. The present study suggests that this adaptation may be lost in athletes with UUPS: this might explain some of their observed symptoms.

          Statistics from

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

          Linked Articles

          • Correction
            BMJ Publishing Group Ltd and British Association of Sport and Exercise Medicine